TY - JOUR
T1 - N-terminal pro-brain natriuretic peptide and heart failure risk among individuals with and without obesity
T2 - The Atherosclerosis Risk in Communities (ARIC) study
AU - Ndumele, Chiadi E.
AU - Matsushita, Kunihiro
AU - Sang, Yingying
AU - Lazo-Elizondo, Mariana
AU - Agarwal, Sunil K.
AU - Nambi, Vijay
AU - Deswal, Anita
AU - Blumenthal, Roger S.
AU - Ballantyne, Christie M.
AU - Coresh, Josef
AU - Selvin, Elizabeth
N1 - Funding Information:
We thank the staff and participants of the ARIC Study for their important contributions. The ARIC Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). This work was supported by the Robert E. Meyerhoff Professorship, a Robert Wood Johnson Amos Medical Faculty Development Award, and an National Institutes of Health/National Heart, Lung, and Blood Institute grant (K23HL12247) awarded to Dr Ndumele and by a National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grant (R01DK089174) awarded to Dr Selvin. Dr Selvin was also supported by National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grant K24DK106414. Reagents for the NT-proBNP assays were donated by Roche Diagnostics.
Publisher Copyright:
© 2016 American Heart Association, Inc.
PY - 2016/2/16
Y1 - 2016/2/16
N2 - Background - Obesity is a risk factor for heart failure (HF) but is associated with lower N-terminal pro-brain natriuretic peptide (NT-proBNP) levels. It is unclear whether the prognostic value and implications of NT-proBNP levels for HF risk differ across body mass index (BMI) categories. Methods and Results - We followed up 12 230 ARIC participants free of prior HF at baseline (visit 2, 1990-1992) with BMI ≥18.5 kg/m2. We quantified and compared the relative and absolute risk associations of NT-proBNP with incident HF across BMI categories. There were 1861 HF events during a median 20.6 years of follow-up. Despite increased HF risk in obesity, a weak inverse association was seen between baseline BMI and NT-proBNP levels (r=-0.10). Nevertheless, higher baseline NT-proBNP was associated with increased HF risk in all BMI categories. NT-proBNP improved HF risk prediction overall, even among those with severe obesity (BMI ≥35 kg/m2; improvement in C statistic, 0.032; 95% confidence interval, 0.011-0.053). However, given the higher HF rates among those with obesity, at each NT-proBNP level, higher BMI was associated with greater absolute HF risk. Indeed, among those with NT-proBNP of 100 to <200 pg/mL, the average 10-year HF risk was <5% among normal-weight individuals but >10% among the severely obese. Conclusions - Despite its inverse relationship with BMI, NT-proBNP provides significant prognostic information on the risk of developing HF even among individuals with obesity. Given the higher baseline HF risk among persons with obesity, even slight elevations in NT-proBNP may have implications for increased absolute HF risk in this population.
AB - Background - Obesity is a risk factor for heart failure (HF) but is associated with lower N-terminal pro-brain natriuretic peptide (NT-proBNP) levels. It is unclear whether the prognostic value and implications of NT-proBNP levels for HF risk differ across body mass index (BMI) categories. Methods and Results - We followed up 12 230 ARIC participants free of prior HF at baseline (visit 2, 1990-1992) with BMI ≥18.5 kg/m2. We quantified and compared the relative and absolute risk associations of NT-proBNP with incident HF across BMI categories. There were 1861 HF events during a median 20.6 years of follow-up. Despite increased HF risk in obesity, a weak inverse association was seen between baseline BMI and NT-proBNP levels (r=-0.10). Nevertheless, higher baseline NT-proBNP was associated with increased HF risk in all BMI categories. NT-proBNP improved HF risk prediction overall, even among those with severe obesity (BMI ≥35 kg/m2; improvement in C statistic, 0.032; 95% confidence interval, 0.011-0.053). However, given the higher HF rates among those with obesity, at each NT-proBNP level, higher BMI was associated with greater absolute HF risk. Indeed, among those with NT-proBNP of 100 to <200 pg/mL, the average 10-year HF risk was <5% among normal-weight individuals but >10% among the severely obese. Conclusions - Despite its inverse relationship with BMI, NT-proBNP provides significant prognostic information on the risk of developing HF even among individuals with obesity. Given the higher baseline HF risk among persons with obesity, even slight elevations in NT-proBNP may have implications for increased absolute HF risk in this population.
KW - epidemiology
KW - heart failure
KW - natriuretic peptides
KW - obesity
KW - risk assessment
UR - http://www.scopus.com/inward/record.url?scp=84958925381&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958925381&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.115.017298
DO - 10.1161/CIRCULATIONAHA.115.017298
M3 - Article
C2 - 26746175
AN - SCOPUS:84958925381
SN - 0009-7322
VL - 133
SP - 631
EP - 638
JO - Circulation
JF - Circulation
IS - 7
ER -